ChemoINTEL test study for ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study is testing a new lab test (called ChemoINTEL) that looks at how your cancer cells respond to chemotherapy drugs used for ovarian cancer. The goal is to see if the test can predict how well the treatment will work for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman 18 years or older.
- You have advanced-stage epithelial ovarian cancer, primary peritoneal carcinomatosis, or fallopian tube carcinoma (newly diagnosed or recurrent).
- You had a sample of your tumor or belly fluid collected before starting chemotherapy.
- You have received at least 3 cycles of standard chemotherapy (such as carboplatin, paclitaxel, or others listed).
- You agree to have your response to chemotherapy checked after the 3rd and 6th cycles using standard tests (like scans or blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
This study tests whether adding a statin (a common cholesterol-lowering drug) to standard chemotherapy can improve outcomes for people with ovarian cancer. It's for women who are about to receive chemotherapy as part of their treatment plan.
This trial tests a combination treatment for advanced ovarian cancer that hasn't been treated before. It combines chemotherapy, a personalized vaccine made from your own immune cells, and a drug called pembrolizumab to help your immune system fight the cancer.
This trial tests adding telmisartan (a blood pressure medicine) to standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based drugs. The goal is to see if the combination can help control the cancer better.
This trial tests a combination of three drugs—pembrolizumab (Keytruda, an immunotherapy), bevacizumab (Avastin, a blood-vessel blocker), and oral cyclophosphamide (a chemotherapy pill)—for women with high-grade ovarian cancer who have only tiny bits of disease left after finishing their initial treatment.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.